Maduck Sean's Form 4 filing
Corcept Therapeutics IncCORT · filed Nov 4, 2026
- Accession no.
- 0001193125-26-447906
- Filed
- Nov 4, 2026, 7:26 PM ET
- Trade date
- Nov 2-3, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.05M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maduck SeanCIK 0001698310 | Other: See Remarks |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Common Stock | MOption exerciseAcquired | +11,841 | $8.27 | +$97,925.07 | 21,779 | Direct | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −11,841 | $81.42F3 | −$964,074.09 | 9,938 | Direct | |
| Nov 3, 2026 | Common Stock | MOption exerciseAcquired | +13,159 | $8.27 | +$108,824.93 | 23,097 | Direct | |
| Nov 3, 2026 | Common Stock | SSaleDisposed | −8,617 | $82.02F4 | −$706,764.62 | 14,480 | Direct | |
| Nov 3, 2026 | Common Stock | SSaleDisposed | −4,542 | $82.68F5 | −$375,512.58 | 9,938 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Common Stock | MOption exerciseDisposed | −11,841 | $0.00 | $0 | 30,145 | Direct | |
| Nov 3, 2026 | Common Stock | MOption exerciseDisposed | −13,159 | $0.00 | $0 | 16,986 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.12 to $82.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.25 to $82.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F5
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.34 to $83.02 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Former President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.